Prognostic utility of negative stress/rest myocardial SPECT studies among patients with different clinical categories of chronic kidney disease: Data from an Egyptian coh

• Main Authors: Mohamed A. Mandour Ali, Haitham Sabry
• Format: Article
• Language: English
• Published: SpringerOpen 2016-09-01
• Series: The Egyptian Heart Journal
• Subjects: NPV; SPECT; Outcome research; CKD
• Online Access: http://www.sciencedirect.com/science/article/pii/S111026081600017X

Prognostic value of negative myocardial SPECT study is well established. However, patients with chronic kidney disease (CKD) are a special group showing increased risk of cardiac events. We thought to investigate the prognostic value of negative SPECT study among patients on regular hemodialysis compared to other clinical categories of CKD. Methods: 186 consecutive patients with CKD and negative SPECT study were enrolled. 93 (50%) were on hemodialysis with an eGFR < 30 mL/min/1.73 m2 (Group I); 25 (13.4%) had uncomplicated renal transplantation with eGFR between 45 and 90 mL/min/1.73 m2 (Group II) and 68 (36.6%) with CKD on conservative management and no prior history of hemodialysis (eGFR between 30 and 60 mL/min/1.73 m2), Group (III). End points (CD, STEMI/NSTEMI, need for revascularization and hospitalized HF) were traced at 6 months, one year and 2 years. Results: Total events in all groups were 5 (2.70%) at 6 months, and 18 (9.70%) and 36 (19.30%) at one year and 2 years respectively. At one year 16 (17.20%) cardiac events happened in Group I compared to one (4.0%) and one (1.50%) event(s) in Groups II and III respectively (p values 0.001). At 2 years, 29 (31.20%) cardiac events happened in Group I while 2 (8.0%) and 5 (7.30%) happened in Groups II and III respectively (p values 0.01, 0.001 respectively). eGFR and duration of hemodialysis were the independent predictors of cardiac events. Conclusion: Despite negative MPI study, patients on hemodialysis showed higher event (including CD, STEMI/NSTEMI and revascularization) rate at one and 2 years of follow-up compared to other clinical categories of CKD.